Mark Shackleton - Publications

Oncology Monash University, Melbourne, Australia, Clayton, Victoria, Australia 
 2006-2009 University of Michigan, Ann Arbor, Ann Arbor, MI 

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Zhang X, Tang JZ, Vergara IA, Zhang Y, Szeto P, Yang L, Mintoff C, Colebatch A, Mcintosh L, Mitchell KA, Shaw E, Rizos H, Long GV, Hayward N, McArthur GA, ... ... Shackleton M, et al. Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma. Molecular Cancer Research : McR. PMID 30833299 DOI: 10.1158/1541-7786.MCR-18-0407  0.48
2017 Noguchi F, Inui S, Fedele C, Shackleton M, Itami S. Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma. Molecular Cancer Therapeutics. 16: 936-947. PMID 28223427 DOI: 10.1158/1535-7163.MCT-15-0235  0.64
2016 Eskiocak U, Ramesh V, Gill JG, Zhao Z, Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Frankel AE, Johnson TM, DeBerardinis RJ, Morrison SJ. Erratum: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications. 7: 13080. PMID 27681157 DOI: 10.1038/ncomms13080  0.88
2016 Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L, Ananda S, Hallo J, Loi S, Scott C, Savas P, ... ... Shackleton M, et al. A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology. PMID 27617737 DOI: 10.1038/nbt.3674  0.64
2016 Eskiocak U, Ramesh V, Gill JG, Zhao Z, Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Johnson TM, DeBerardinis RJ, Morrison SJ. Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications. 7: 12336. PMID 27545456 DOI: 10.1038/ncomms12336  0.88
2016 Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E, Ruszkiewicz A, Brown MP, Bonder CS, Shackleton M, Ebert LM. Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget. PMID 27340778 DOI: 10.18632/oncotarget.10216  0.64
2016 Ebert LM, Tan LY, Johan MZ, Min KK, Cockshell MP, Parham KA, Betterman KL, Szeto P, Boyle S, Silva L, Peng A, Zhang Y, Ruszkiewicz A, Zannettino AC, Gronthos S, ... ... Shackleton M, et al. A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis. PMID 27338829 DOI: 10.1007/s10456-016-9520-y  0.48
2015 Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, ... ... Shackleton M, et al. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research. PMID 26627015 DOI: 10.1158/0008-5472.CAN-15-1877  0.88
2015 Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DH, Koh CM, Rambow F, Fiers M, Rogiers A, Radaelli E, Al-Haddawi M, Tan SY, Hermans E, Amant F, ... ... Shackleton M, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. The Journal of Clinical Investigation. PMID 26595814 DOI: 10.1172/JCI82534  0.88
2015 Wilmott JS, Field MA, Johansson PA, Kakavand H, Shang P, De Paoli-Iseppi R, Vilain RE, Pupo GM, Tembe V, Jakrot V, Shang CA, Cebon J, Shackleton M, Fitzgerald A, Thompson JF, et al. Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology. PMID 26517638 DOI: 10.1097/PAT.0000000000000324  0.88
2015 Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, et al. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Science Signaling. 8: ra82. PMID 26286024 DOI: 10.1126/scisignal.aab1111  0.88
2015 He M, Lovell J, Ng BL, Spillane J, Speakman D, Henderson MA, Shackleton M, Gyorki DE. Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication. Journal of Surgical Oncology. 111: 980-4. PMID 26080731 DOI: 10.1002/jso.23938  0.88
2015 Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, ... ... Shackleton M, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 521: 489-94. PMID 26017449 DOI: 10.1038/nature14410  0.88
2015 Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer (Oxford, England : 1990). 51: 1435-43. PMID 25980594 DOI: 10.1016/j.ejca.2015.04.010  0.88
2012 Quintana E, Piskounova E, Shackleton M, Weinberg D, Eskiocak U, Fullen DR, Johnson TM, Morrison SJ. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Science Translational Medicine. 4: 159ra149. PMID 23136044 DOI: 10.1126/scitranslmed.3004599  0.88
2012 Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, ... ... Shackleton M, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine. 18: 1239-47. PMID 22820643 DOI: 10.1038/nm.2863  0.88
2012 Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. Plos One. 7: e36924. PMID 22666336 DOI: 10.1371/journal.pone.0036924  0.88
2011 Carter CC, McNamara LA, Onafuwa-Nuga A, Shackleton M, Riddell J, Bixby D, Savona MR, Morrison SJ, Collins KL. HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host & Microbe. 9: 223-34. PMID 21402361 DOI: 10.1016/j.chom.2011.02.005  0.88
2010 Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 18: 510-23. PMID 21075313 DOI: 10.1016/j.ccr.2010.10.012  0.88
2010 Shackleton M, Quintana E. Progress in understanding melanoma propagation Molecular Oncology. 4: 451-457. PMID 20655286 DOI: 10.1016/j.molonc.2010.06.006  0.88
2009 Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 138: 822-9. PMID 19737509 DOI: 10.1016/j.cell.2009.08.017  0.88
2009 Shackleton M, O'Reilly LA, Sutherland KD, Bath ML, Ellis S, Strasser A, Visvader JE, Lindeman GJ. Impaired lactation in mice expressing dominant-negative FADD in mammary epithelium. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 238: 1010-6. PMID 19301394 DOI: 10.1002/dvdy.21917  0.88
2009 Johnson TM, Shackleton MJ, Quintana E, Fullen DR, Sabel MS. Melanoma: Do we need a hatchet or a scalpel? Archives of Dermatology. 145: 307-308. PMID 19289763 DOI: 10.1001/archdermatol.2009.3  0.88
2008 Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 456: 593-8. PMID 19052619 DOI: 10.1038/nature07567  0.88
2008 Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Research. 68: 7711-7. PMID 18829523 DOI: 10.1158/0008-5472.CAN-08-1949  0.88
2007 Vaillant F, Asselin-Labat ML, Shackleton M, Lindeman GJ, Visvader JE. The emerging picture of the mouse mammary stem cell. Stem Cell Reviews. 3: 114-23. PMID 17873344 DOI: 10.1007/s12015-007-0018-2  0.88
2007 Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, van der Wees J, Lindeman GJ, Visvader JE. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nature Cell Biology. 9: 201-9. PMID 17187062 DOI: 10.1038/ncb1530  0.88
2006 Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ. Steroid hormone receptor status of mouse mammary stem cells. Journal of the National Cancer Institute. 98: 1011-4. PMID 16849684 DOI: 10.1093/jnci/djj267  0.88
2006 Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature. 439: 84-8. PMID 16397499 DOI: 10.1038/nature04372  0.88
2005 Sum EY, Shackleton M, Hahm K, Thomas RM, O'Reilly LA, Wagner KU, Lindeman GJ, Visvader JE. Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development. Oncogene. 24: 4820-8. PMID 15856027 DOI: 10.1038/sj.onc.1208638  0.88
Show low-probability matches.